Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11/2002

01-01-2002 | Original Article

The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression

Authors: Gabriel A. Rabinovich, Natalia Rubinstein, Pablo Matar, Viviana Rozados, Silvia Gervasoni, Graciela O. Scharovsky

Published in: Cancer Immunology, Immunotherapy | Issue 11/2002

Login to get access
Metadata
Title
The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression
Authors
Gabriel A. Rabinovich
Natalia Rubinstein
Pablo Matar
Viviana Rozados
Silvia Gervasoni
Graciela O. Scharovsky
Publication date
01-01-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-001-0238-2

Other articles of this Issue 11/2002

Cancer Immunology, Immunotherapy 11/2002 Go to the issue

Original Article

Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer

Original Article

Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model

Original Article

HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones

Review

Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines

Original Article

Down-regulation of IL-2 receptor α (CD25) characterizes human γδ-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits